2016年8月30日 · The need for a head-to-head comparison of newer P2Y 12 inhibitors motivated us to perform the PRAGUE-18 study, which was a randomized, multicenter study designed to compare the efficacy and safety of prasugrel and ticagrelor in patients with AMI treated with primary or immediate PCI and to assess the percentages, reasons, and consequences of ...

2019年9月1日 · In this multicenter, randomized, open-label trial, we randomly assigned patients who presented with acute coronary syndromes and for whom invasive evaluation was planned to receive either...

2016年11月22日 · Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study Circulation . 2016 Nov 22;134(21):1603-1612. doi: 10.1161/CIRCULATIONAHA.116.024823.

2018年1月30日 · The multicenter PRAGUE-18 (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction) study was the first randomized head-to-head comparison of prasugrel and ticagrelor, with regard to efficacy and safety, in patients with AMI undergoing primary percutaneous coronary intervention (pPCI) strategy.

2017年11月14日 · The PRAGUE-18 trial showed similar efficacy for either prasugrel or ticagrelor during primary PCI. The goal of the trial was to evaluate treatment with prasugrel versus ticagrelor among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).

Rome, Italy 30 August 2016: The antiplatelet drugs prasugrel and ticagrelor had similar safety and efficacy among patients with acute myocardial infarction and ST segment elevations (STEMI), according to results of PRAGUE-18, the first randomised, head-to-head comparison of the drugs.

PRAGUE-18 was designed with a hypothesis that ticagrelor would be su-perior to prasugrel and to have 80% power to show a 38.5% relative difference. In absolute terms, the inves-tigators estimated an event rate of 6.5% at 30 days and an absolute risk reduction of 2.5% with ticagrelor.

2017年12月19日 · One-year outcomes of prasugrel versus ticagrelor in acute myocardial infarction treated with primary angioplasty: The PRAGUE-18 study. J Am Coll Cardiol 2017 Nov 9 [Epub ahead of print]. Bottom line: PRAGUE-18 was underpowered to identify clinically-important differences & was at high risk of bias.

• The multicenter randomized PRAGUE-18 study is the first head-to-head comparison of prasugrel and ticagrelor in acute myocardial infarction treated with primary or immediate percutaneous coronary intervention. • The study was designed as a superiority trial and was stopped prematurely because of futility after enrollment of 1230 patients.

discharge switch from prasu/tica to clopidogrel. Signed informed consent. Known hypersensitivity to prasugrel or ticagrelor. Thus, some patients decided to switch after discharge to clopidogrel …